Certificate of Analysis

Semaglutide: third-party lab results, COA-2026-9433

Compound
Semaglutide
Certificate
COA-2026-9433
Purity
98.50%
Method
HPLC (RP-HPLC / HPLC-RTM)
Identity
Confirmed
Testing lab
Titreon Analytical
Quality system
Aligned to ISO/IEC 17025:2017
Lot
SG-2601
CAS
910463-68-2
Issued
2026-07-02

Mass spec: Deconvoluted neutral mass 4113.6 Da, matches theoretical 4113.6 Da, identity confirmed by LC-MS, ESI positive.

Full assay panel, Titreon Analytical, 2026-07-02
TestResult
Peptide Purity (HPLC)98.50% (spec >= 95.0%), PASS
Net Peptide Content (HPLC / AAA)10.00 mg (report only), REPORTED
Identity (HPLC-RTM)Semaglutide, Confirmed, PASS
Fentanyl ScreenNot Detected (immunoassay, 50 ng/mL), PASS
Water (Karl Fischer, USP 921)4.50% w/w (spec NMT 8.0% w/w), PASS
Counterion (acetate, ion chromatography)7.80% w/w (report only), REPORTED
Residual Solvents (TFA, USP 467)Not Detected, PASS
Gross Fill Weight (gravimetric)11.63 mg (report only), REPORTED
Arsenic (As, ICP-MS)Not Detected (spec NMT 1.5 ppm), PASS
Cadmium (Cd, ICP-MS)Not Detected (spec NMT 0.5 ppm), PASS
Chromium (Cr, ICP-MS)Not Detected (spec NMT 10 ppm), PASS
Mercury (Hg, ICP-MS)Not Detected (spec NMT 1.5 ppm), PASS
Lead (Pb, ICP-MS)Not Detected (spec NMT 1 ppm), PASS
Sterility (USP 71)No Growth, PASS
Bioburden (USP 61)< 1 CFU/mL (spec < 10 CFU/mL), PASS
Bacterial Endotoxin (USP 85)0.8 EU/vial (spec NMT 5 EU/mL), PASS
Download the full COA (PDF) See all Aion certificates Signed and released by Titreon Analytical, whose quality system is aligned to ISO/IEC 17025:2017.

The Aion Semaglutide batch was tested at 98.50 percent purity by HPLC, with identity confirmed by mass spectrometry. The certificate is issued by Titreon Analytical, which operates a quality system aligned to ISO/IEC 17025:2017, under certificate COA-2026-9433.

The panel covers identity confirmation (HPLC-RTM), a fentanyl screen (not detected), water content by Karl Fischer, residual solvents, five heavy metals by ICP-MS (all not detected), sterility, bioburden, and bacterial endotoxin at 0.8 EU per vial. Every specification passed.

Purity is measured by reversed-phase HPLC. Mass spec (LC-MS, ESI positive) returned a deconvoluted neutral mass of 4113.6 Da, matching the theoretical mass of semaglutide, confirming identity independently of the purity figure.

This certificate documents laboratory identity and purity testing only. The compound is sold for research use only, is not approved by the FDA for human use, and nothing here is medical advice.